|
| Index | - | P/E | - | EPS (ttm) | -2.19 | Insider Own | 0.26% | Shs Outstand | 3.11M | Perf Week | 1.92% |
| Market Cap | 5.03M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 3.09M | Perf Month | -9.40% |
| Income | -6.80M | PEG | - | EPS next Q | - | Inst Own | 5.80% | Short Float / Ratio | 4.79% / 0.07 | Perf Quarter | 4.95% |
| Sales | 12.60M | P/S | 0.40 | EPS this Y | 17.10% | Inst Trans | -2.13% | Short Interest | 0.15M | Perf Half Y | -51.15% |
| Book/sh | 1.79 | P/B | 0.59 | EPS next Y | - | ROA | -41.80% | Target Price | - | Perf Year | -68.45% |
| Cash/sh | 0.55 | P/C | 1.94 | EPS next 5Y | - | ROE | -92.90% | 52W Range | 0.90 - 4.25 | Perf YTD | -5.36% |
| Dividend | - | P/FCF | - | EPS past 5Y | 36.40% | ROI | -50.90% | 52W High | -75.06% | Beta | 1.20 |
| Dividend % | - | Quick Ratio | 2.10 | Sales past 5Y | -0.30% | Gross Margin | 31.20% | 52W Low | 17.78% | ATR | 0.12 |
| Employees | 12 | Current Ratio | 2.90 | Sales Q/Q | 0.00% | Oper. Margin | -46.30% | RSI (14) | 45.96 | Volatility | 15.21% 10.66% |
| Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | -103.60% | Profit Margin | -54.10% | Rel Volume | 0.08 | Prev Close | 0.94 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 2.05M | Price | 1.06 |
| Recom | 2.00 | SMA20 | 1.40% | SMA50 | -19.45% | SMA200 | -49.10% | Volume | 165,310 | Change | 12.44% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite